Last reviewed · How we verify

Tacrolimus Sustained-release Capsules

RenJi Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Tacrolimus Sustained-release Capsules is a Small molecule drug developed by RenJi Hospital. It is currently FDA-approved.

Tacrolimus Sustained-release Capsules are a small molecule inhibitor of the FK506-binding protein 1A, used to treat various conditions including renal transplant rejection, liver transplant rejection, and nephrotic syndrome. They are indicated for use in renal transplant recipients, liver transplant recipients, and patients with nephrotic syndrome, among other conditions.

At a glance

Generic nameTacrolimus Sustained-release Capsules
SponsorRenJi Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tacrolimus Sustained-release Capsules

What is Tacrolimus Sustained-release Capsules?

Tacrolimus Sustained-release Capsules is a Small molecule drug developed by RenJi Hospital.

Who makes Tacrolimus Sustained-release Capsules?

Tacrolimus Sustained-release Capsules is developed and marketed by RenJi Hospital (see full RenJi Hospital pipeline at /company/renji-hospital).

What development phase is Tacrolimus Sustained-release Capsules in?

Tacrolimus Sustained-release Capsules is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing